{"favorite_id": 10182, "calc_type": "calculator", "dosing": false, "full_title_en": "Psoriasis Area and Severity Index (PASI)", "short_title_en": "Psoriasis Area and Severity Index (PASI)", "medium_description_en": "Quantifies severity of psoriasis.", "short_description_en": "Psoriasis severity.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Autoimmune Disorders", "Psoriasis"], "specialty_en": ["Allergy and Immunology", "Dermatology", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Rash"], "system_en": ["Dermatologic", "Immunologic"], "search_abbreviation_en": ["Pasi", "psoriasis", "pasi", "psoriasis severity"], "slug": "psoriasis-area-severity-index-pasi", "seo": {"meta_description_en": "The Psoriasis Area and Severity Index (PASI) quantifies severity of psoriasis.", "keywords_en": "Pasi, psoriasis, pasi, psoriasis severity"}, "content": {"how_to_use": {"use_case_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patients with psoriasis.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Use with caution in patients with smaller areas of involvement, as the score is less sensitive in those cases.</p>\n</li>\n</ul>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-f5c2a4d5-7fff-3b7b-53eb-72816e5395f7\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Initially developed to assess treatment efficacy of retinoids.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PASI is the most widely used psoriasis clinical severity score.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Validated using palm method of body surface area estimation (patient&rsquo;s palm, excluding fingers, roughly correlates to 1% <abbr title=\"Body surface area\">BSA</abbr>).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PASI is neither a linear nor normally distributed score, as it is less sensitive at lower end of scale, and accurate PASI assessment requires some level of&nbsp;clinical gestalt in assigning points.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PASI is limited by lack of interrater and intrarater reliability, and lack of utility in detecting change in mild psoriasis.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Calculating the PASI can be error-prone if not done systematically.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-03eeaa18-7fff-6b10-d609-034ccac8127e\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">May be used to track disease progression and help guide treatment (e.g. retinoids).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In some countries (e.g. Australia), PASI is used to determine eligibility for government-subsidized prescription drugs.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Used in clinical trials of therapies to treat psoriasis.</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-c6cb3a14-7fff-0321-505c-6fcee2fd328e\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Higher PASI scores indicate more severe psoriasis and therefore likely warrant more aggressive treatment.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">May be trended over time to assess treatment efficacy.</p>\n</li>\n</ul>", "management_en": "<p>When measured serially:</p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span id=\"docs-internal-guid-37555970-7fff-3ed3-a06a-eafb69c080dd\">T<span id=\"docs-internal-guid-37555970-7fff-3ed3-a06a-eafb69c080dd\">he term<span id=\"docs-internal-guid-37555970-7fff-3ed3-a06a-eafb69c080dd\"> &ldquo;PASI 75&rdquo; indicates a 75% reduction (improvement) in PASI, and is generally considered a &ldquo;good response&rdquo; to therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span id=\"docs-internal-guid-37555970-7fff-3ed3-a06a-eafb69c080dd\">PASI 50 to 74 is considered partial response, and PASI &lt;50 is considered treatment failure. </p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span id=\"docs-internal-guid-37555970-7fff-3ed3-a06a-eafb69c080dd\">Patients with PASI 75 can likely continue current management, and those with PASI &lt;50 can be considered for more aggressive treatment such as with biologics.</p>\n</li>\n</ul>", "critical_actions_en": "<p><span id=\"docs-internal-guid-6c3ea390-7fff-9055-0fec-b4e7342304ff\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Consultation with a dermatologist is warranted in patients with psoriasis.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PASI assessments become more reliable with experience in scoring.</p>\n</li>\n</ul>"}, "about": {"formula_en": "<p dir=\"ltr\">Total PASI = addition of PASI for each body region (i.e., head/neck, upper limbs, trunk, and lower limbs)</p>\n<p dir=\"ltr\">PASI for each body region = lesion severity x&nbsp;percentage of area affected x body surface area, defined as below</p>\n<p dir=\"ltr\">Lesion severity for each body region = erythema + induration/thickness + desquamation/scaling, defined as below</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"224\" /><col width=\"130\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><b>Lesion characteristic (separately scored for head/neck, upper limbs, trunk, and lower limbs)</b></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Erythema</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">None</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Slight</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe</p>\n</td>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Very severe</p>\n</td>\n<td>\n<p dir=\"ltr\">4</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Induration/thickness</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">None</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Slight</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe</p>\n</td>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Very severe</p>\n</td>\n<td>\n<p dir=\"ltr\">4</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Desquamation/scaling</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">None</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Slight</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Moderate</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Severe</p>\n</td>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Very severe</p>\n</td>\n<td>\n<p dir=\"ltr\">4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>\n<p dir=\"ltr\"><strong>Percentage of area affected*:</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"224\" /><col width=\"129\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Percentage of area affected</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0%</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1-9%</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">10-29%</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">30-49%</p>\n</td>\n<td>\n<p dir=\"ltr\">3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">50-69%</p>\n</td>\n<td>\n<p dir=\"ltr\">4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">70-89%</p>\n</td>\n<td>\n<p dir=\"ltr\">5</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">90-100%</p>\n</td>\n<td>\n<p dir=\"ltr\">6</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>*Validated using palm method of body surface area estimation (patient&rsquo;s palm, excluding fingers, roughly correlates to 1% BSA).</p>\n<p></p>\n<p dir=\"ltr\"><strong>Body surface area:</strong></p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"224\" /><col width=\"128\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Region</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><b>Constants</b></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Head/neck</p>\n</td>\n<td>\n<p dir=\"ltr\">0.1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Upper limbs</p>\n</td>\n<td>\n<p dir=\"ltr\">0.2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Trunk</p>\n</td>\n<td>\n<p dir=\"ltr\">0.3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Lower limbs</p>\n</td>\n<td>\n<p dir=\"ltr\">0.4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>", "more_info_en": "<p>Interpretation:</p>\n<p>Higher PASI scores indicate higher severity of psoriasis. Scores range from 0 (no disease) to 72 (maximal disease severity).</p>", "evidence_based_medicine_en": "<p dir=\"ltr\">The PASI was originally developed in 1978 to assess the effects of retinoids in psoriasis (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/357213\" target=\"_blank\">Fredriksson 1978</a>). PASI is recommended by many major guidelines, including the <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20857129\" target=\"_blank\">European Consensus Programme for treatment goals in psoriasis</a>, <a href=\"https://www.dermcoll.edu.au/wp-content/uploads/ACD-Consensus-Statement-Treatment-goals-for-psoriasis-March-2017.pdf\" target=\"_blank\">Australasian College of Dermatologists guidelines</a>, and <a href=\"https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis\" target=\"_blank\">American Academy of Dermatologists guidelines</a>. Despite being the most widely used score for assessing severity of psoriasis, it has several limitations.</p>\n<p dir=\"ltr\">PASI was initially thought to be a poor clinical outcome measure, as reliability and variability was difficult to measure. Because it excludes primary signs and symptoms of psoriasis, content validity is also difficult to measure. Criterion variability is restricted, as there is lack of a true gold standard measure of psoriasis severity (PASI is sometimes considered the gold standard). Reliability was thought to require additional research. The biggest drawback of the PASI was its lack of sensitivity (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15785046\" target=\"_blank\">Schmitt 2005</a>).</p>\n<p dir=\"ltr\">A 2010 systematic review showed that, despite its limitations, PASI was the most extensively studied and validated score for assessing plaque psoriasis severity (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20443995\" target=\"_blank\">Puzenat 2010</a>). It was shown to have good internal consistency and moderate interobserver variation, and is highly reproducible when performed by trained individuals with low intraobserver variability.</p>\n<p dir=\"ltr\">In a small study done by&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/16965419\" target=\"_blank\">Berth-Jones et al (2006)</a>, PASI was noted to have substantial interrater reliability and intrarater reliability. This study was carried out on a single day on 14 raters. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/25917214\" target=\"_blank\">Simpson et al (2015</a>) showed that PASI has good construct validity, with positive correlation with quality of life measures. In clinical trials, 75% improvement in PASI (PASI 75) has been widely accepted as clinically meaningful improvement (indicative of treatment success) (<a href=\"https://ard.bmj.com/content/64/suppl_2/ii65\" target=\"_blank\">Feldman and Krueger 2005</a>).</p>\n<p dir=\"ltr\"><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20043014\" target=\"_blank\">Spuls et al (2010)</a> evaluated PASI using clinimetric criteria and found limitations including low response distribution, no consensus on interpretability, and low responsiveness in mild disease. Another major limitation is questionable accuracy in scorers with limited experience. Intrarater variation for PASI among inexperienced physicians (&sigma; = 3.2) is almost&nbsp;three times higher than that for experienced investigators (&sigma; = 1.2); i.e., PASI assessment gets more reliable with experience of clinician making the assessment (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/15389191\" target=\"_blank\">Langley 2004</a>).</p>\n<p><span id=\"docs-internal-guid-a354606e-7fff-e229-0e9a-7a40eeb623a4\">Another disadvantage of the PASI is the lack of sensitivity at the lower end of the range. PASI is not a linear scale. Due to this, it is not as useful in mild psoriasis (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/20443995\" target=\"_blank\">Puzenat 2010</a>).</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/357213", "text": "Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/15389191", "text": "Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51(4):563-9."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/15785046", "text": "Schmitt J, Wozel G. The Psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Clinical and Laboratory Investigations. 2005; 210: 194-199. "}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/15708941", "text": "Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005; 64: 65-68."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/16965419", "text": "Berth-Jones J, Grotzinger K, Rainville C et al.  A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physicians Global Assessment and Lattice System Physicians Global Assessment. Clinical and Laboratory Investigations. 2006; 155: 707-713."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/20043014", "text": "Spuls PI, Lecluse LLA, Poulsen MNF et al. How Good are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review. Journal of Investigative Dermatology. 2010; 130 (4): 933-943."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/20443995", "text": "Puzenat E, Bronsard V, Gourraud PA et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. European Academy of Dermatology and Venereology. 2010; 24: 10-16."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/25917214", "text": "Simpson MJ, Chow C, Morgenstem H et al. Comparison of 3 methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of LS-PGA, PASI and Static Physician\u2019s Global assessment. European Academy of Dermatology and Venereology. 2015; 29: 1415-1420."}], "Clinical Practice Guidelines": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/20857129", "text": "Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10."}, {"href": "https://www.dermcoll.edu.au/wp-content/uploads/ACD-Consensus-Statement-Treatment-goals-for-psoriasis-March-2017.pdf", "text": "Australiasian College of Dermatologists. The Australasian College of Dermatologist Consensus Statement. Treatment goals for psoriasis 2017. https://www.dermcoll.edu.au/wp-content/uploads/ACD-Consensus-Statement-Treatment-goals-for-psoriasis-March-2017.pdf. Accessed March 19, 2019."}, {"href": "https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis", "text": "Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113."}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "", "firstName": "Zhi", "img": "", "lastName": "Low", "name": "Zhi Mei Low, MBBS", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": [{"name": "Johannes S. Kern, MD, PhD"}]}, "creator": [{"name": "Dr. Torsten Fredriksson", "creator_info": {"about_en": "<p>Torsten Fredriksson, MD, is a physician in the department of dermatology at the Karolinska Institute in Sweden. Dr. Fredriksson\u2019s primary research is focused on topical treatments for conditions like psoriasis, dermatomycosis, and tinea versicolor.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/default.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fredriksson+T%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "subheading", "subheading": "Head/neck", "subheading_instructions": ""}, {"type": "radio", "label_en": "Erythema", "name": "head_ery", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Induration/thickness", "name": "head_indu", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Desquamation/scaling", "name": "head_scale", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Percentage of head/neck affected", "name": "head_percent", "options": [{"label": "0%", "value": 0}, {"label": "1-9%", "value": 1}, {"label": "10-29%", "value": 2}, {"label": "30-49%", "value": 3}, {"label": "50-69%", "value": 4}, {"label": "70-89%", "value": 5}, {"label": "90-100%", "value": 6}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Upper limbs", "subheading_instructions": ""}, {"type": "radio", "label_en": "Erythema", "name": "upper_ery", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Induration/thickness", "name": "upper_indu", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Desquamation/scaling", "name": "upper_scale", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Percentage of upper limbs affected", "name": "upper_percent", "options": [{"label": "0%", "value": 0}, {"label": "1-9%", "value": 1}, {"label": "10-29%", "value": 2}, {"label": "30-49%", "value": 3}, {"label": "50-69%", "value": 4}, {"label": "70-89%", "value": 5}, {"label": "90-100%", "value": 6}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Trunk", "subheading_instructions": ""}, {"type": "radio", "label_en": "Erythema", "name": "trunk_ery", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Induration/thickness", "name": "trunk_indu", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Desquamation/scaling", "name": "trunk_scale", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Percentage of trunk affected", "name": "trunk_percent", "options": [{"label": "0%", "value": 0}, {"label": "1-9%", "value": 1}, {"label": "10-29%", "value": 2}, {"label": "30-49%", "value": 3}, {"label": "50-69%", "value": 4}, {"label": "70-89%", "value": 5}, {"label": "90-100%", "value": 6}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Lower limbs", "subheading_instructions": ""}, {"type": "radio", "label_en": "Erythema", "name": "lower_ery", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Induration/thickness", "name": "lower_indu", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Desquamation/scaling", "name": "lower_scale", "options": [{"label": "None", "value": 0}, {"label": "Slight", "value": 1}, {"label": "Moderate", "value": 2}, {"label": "Severe", "value": 3}, {"label": "Very severe", "value": 4}], "conditionality": "", "show_points": false, "default": 0, "optional": false}, {"type": "radio", "label_en": "Percentage of lower limbs affected", "name": "lower_percent", "options": [{"label": "0%", "value": 0}, {"label": "1-9%", "value": 1}, {"label": "10-29%", "value": 2}, {"label": "30-49%", "value": 3}, {"label": "50-69%", "value": 4}, {"label": "70-89%", "value": 5}, {"label": "90-100%", "value": 6}], "conditionality": "", "show_points": false, "default": 0, "optional": false}], "md5": "90661d69227ceae51a1b5fea3a174988", "cmeVersion": "10182.1", "related_calcs": [{"calcId": 10099, "short_title_en": "SLEDAI-2K for Lupus", "slug": "systemic-lupus-erythematosus-disease-activity-index-2000-sledai-2k"}, {"calcId": 10226, "short_title_en": "Urticaria Activity Score (UAS)", "slug": "urticaria-activity-score-uas"}, {"calcId": 2040, "short_title_en": "Steroid Conversion", "slug": "steroid-conversion-calculator"}]}